The U.S. Food and Drug Administration has approved Novartis' (NVS) Cosentyx or secukinumab for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy.
The Cosentyx approval was based on two Phase III studies evaluating the use of Cosentyx in children aged 6 to less than 18 years with plaque psoriasis. The safety profile reported in the trials was consistent with the safety profile reported in adult plaque psoriasis trials. No new safety signals were observed, Novartis said in a statement.
According to the company, the approved pediatric dosing for Cosentyx is 75 mg or 150 mg depending on the child's weight at the time of dosing and is administered by subcutaneous injection every four weeks after an initial loading regimen.
Cosentyx is fully human biologic that directly inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA)14,15,16.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.